11/20/2019 | HY | Fitch assigns Jaguar Land Rover notes BB-
|
11/15/2006 | BT | Acambis at neutral by Merrill
|
11/14/2006 | BT | Acambis on hold by Jefferies
|
11/14/2006 | BT | Market Commentary: Acambis plunges on surprise loss of new U.S. vaccine contract bid; World Heart lower; Anadys better
|
11/7/2006 | BT | Acambis third-quarter revenue down, company reports net profit of £4.8 million
|
11/7/2006 | BT | Acambis retains neutral rating from Merrill
|
11/7/2006 | BT | Jefferies puts Acambis on hold
|
9/22/2006 | BT | Acambis on hold by Jefferies
|
9/21/2006 | BT | Acambis on hold by Jefferies
|
9/13/2006 | BT | Acambis says future cash position better with $30 million ACAM2000 order, litigation award
|
9/13/2006 | BT | Merrill keeps Acambis at neutral
|
9/12/2006 | BT | Acambis to receive $19 million in Arilvax settlement
|
9/12/2006 | BT | Acambis: Early phase 2 results for West Nile virus vaccine 'encouraging'
|
9/7/2006 | BT | Acambis wins vaccine technology patent case against Bavarian Nordic
|
7/31/2006 | BT | Acambis says immunogenicity results of phase 2 trial of smallpox vaccine consistent with phase 1 findings
|
7/27/2006 | BT | Acambis rated at hold by Jefferies
|
7/26/2006 | BT | Merrill has Acambis at neutral
|
7/17/2006 | BT | Merrill has Acambis at neutral
|
5/19/2006 | BT | Acambis, Baxter oppose European MVA patent for smallpox
|
5/9/2006 | BT | Merrill keeps Acambis at neutral
|
3/10/2006 | BT | Acambis retains neutral rating from Merrill
|
3/9/2006 | BT | Acambis retained at neutral by Merrill
|
2/15/2006 | BT | Acambis: C. difficile vaccine elicits antibody responses in phase 1 study
|
1/30/2006 | BT | Merrill stays neutral on Acambis
|
1/18/2006 | BT | Acambis submits Biologics License from FDA for investigational smallpox vaccine
|
1/18/2006 | BT | Acambis retained at neutral by Merrill
|
12/20/2005 | BT | Acambis begins phase 2 study of West Nile virus vaccine
|
11/28/2005 | BT | Acambis initiates phase 1 trial of clostridium difficile vaccine
|
11/16/2005 | BT | Acambis retained by Merrill Lynch at neutral
|
11/15/2005 | BT | Acambis starts phase 3 trial of vaccine for Japanese encephalitis
|
11/15/2005 | BT | Acambis remains neutral, Merrill Lynch says
|
11/8/2005 | BT | Acambis, Bharat Biotech form agreement to produce Japanese encephalitis vaccine
|
9/6/2005 | BT | Acambis retained by Merrill Lynch at neutral
|
8/22/2005 | BT | Acambis retained by Merrill at neutral
|
8/22/2005 | BT | Market Commentary: Alpharma gains on deal chatter; OSI plunges, Eyetech up on deal; QLT higher; Acambis slides
|
8/16/2005 | BT | Market Commentary: Kosan retreats further after pulling follow-on; Nektar slips; Acambis off, Electro-Optical IPO seen delayed
|
8/4/2005 | BT | Acambis maintained by Merrill at neutral
|
7/21/2005 | BT | Acambis, Crucell poised to strengthen, Merrill vaccine biodefense report says
|
7/13/2005 | BT | Serono may progress while Tysabri slows, Merrill bio/pharma earnings preview says
|
7/8/2005 | BT | Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
|
7/8/2005 | BT | Acambis acknowledges merger talks, but says discussions are over now
|
7/8/2005 | BT | Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
|